Evidence map›Paper›PMID 41800366›Full record

ReviewActa gastroenterologica Latinoamericana

[The Usefulness of Neuromodulators in Clinical Practice: The Gastroenterologist's Viewpoint].

Karla Rocío García-Zermeño, Jorge E Aquino-Matus, Joanna Jiménez Pavón, José María Remes-Troche

Abstract readEnglish AbstractReview
In one paragraph

Review in Acta gastroenterologica Latinoamericana. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Karla Rocío García-ZermeñoCentro Integral de Gastroenterología y Motilidad Avanzada (CIGMA), Boca del Río, Veracruz, México. Centro Integral de Gastroenterología y Motilidad Avanzada (CIGMA) Boca del RíoVeracruz México.ORCID https://orcid.org/0009-0008-7333-6150
Jorge E Aquino-MatusHospital Médica Sur, Unidad de Enfermedades Digestivas y Obesidad, Ciudad de México, México. Hospital Médica Sur Ciudad de México México.ORCID https://orcid.org/0000-0002-3704-6825
Joanna Jiménez PavónDepartamento de Farmacogenética, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Ciudad de México, México. Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz Ciudad de México México.ORCID https://orcid.org/0000-0002-3654-9922
José María Remes-TrocheLaboratorio de Fisiología Digestiva y Motilidad Gastrointestinal. Instituto de Investigaciones Médico-Biológicas, Universidad Veracruzana, Veracruz, México. México. Universidad Veracruzana Instituto de Investigaciones Médico-Biológicas Universidad Veracruzana Veracruz Mexico.ORCID https://orcid.org/0000-0001-8478-9659

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuromodulators have become a fundamental tool in modern gastroenterology, particularly for disorders involving brain-gut interaction. Originally developed for the management of psychiatric disorders, these drugs have demonstrated the ability to modulate visceral pain, intestinal hypersensitivity, and gastrointestinal motility, acting through both central and peripheral mechanisms. The most widely used neuromodulators included tricyclic antidepressants, which are effective in reducing abdominal pain; selective serotonin reuptake inhibitors, which are useful for patients with comorbid anxiety or depression; and serotonin-norepinephrine reuptake inhibitors, which are used for visceral pain with neuropathic features. Other drugs, such as gabapentinoids, mirtazapine, buspirone, and certain antipsychotics, have also shown benefits in specific phenotypes. Drug selection depends on the patient´s clinical profile, comorbidities, tolerability, and risk of adverse effects, particularly for elderly and polymedicated patients. Neuromodulator management is characterized by the use of low initial doses with gradual increases and close patient monitoring. In addition, a multidisciplinary approach integrating non-pharmacological interventions such as cognitive-behavioral therapy, gut-directed hypnotherapy, and mindfulness-based programs, is recommended. This combination enhances clinical effectiveness, reduces stigma, and improves quality of life, consolidating neuromodulators as an essential part of the comprehensive treatment of disorders of brain-gut interaction.

Indexed as

antidepressantsbrain-gut interaction disordersmicrobiotaNeuromodulatorstricyclics

Identifiers

PMID41800366
PMCPMC12965155

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.